A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy

Conditions: Duchenne Muscular Dystrophy Interventions: Drug: BMN 351 Sponsors: BioMarin Pharmaceutical Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials